18 November 2020AmericasChristopher Bright and Nathan Smith
The doctrine of equivalents in the medtech arena
Medtech—and its resultant impact on global healthcare—could not be more urgently needed than now. Benefiting from the convergence of medical and technological advances, medtech promises not only new medical devices, diagnostics and treatments, but also new channels for more effectively delivering healthcare, all with better outcomes.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
4 June 2026 Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.
3 June 2026 A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.
1 June 2026 A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.